Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097188 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00097188 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 104 participants.
The verdict
NCT00097188, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097188
The ClinicalTrials.gov registry entry for NCT00097188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT00097188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097188 about?
NCT00097188 is a clinical study titled "A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis". This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
What is the current status of trial NCT00097188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2004-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00097188?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00097188?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.